3 Papers
Hui Wei is an academic researcher from Guangdong Pharmaceutical University. The author has contributed to research in topics: Acetylcholinesterase & Tacrine. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Tacrine–propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer’s disease
TL;DR: Compounds 3a and 3b could be considered as potential lead compounds for the treatment of AD and other AChE related diseases, such as schizophrenia, glaucoma and myasthenia gravis.
64
Design, synthesis, and evaluation of multitarget-directed ligands against Alzheimer's disease based on the fusion of donepezil and curcumin
TL;DR: By fusing donepezil and curcumin, a novel series of compounds were obtained as multitarget-directed ligands against Alzheimer's disease and compound 11b displayed potent acetylcholinesterase inhibition and the highest BuChE/AChE selectivity.
58
Synthesis and biological evaluation of berberine-thiophenyl hybrids as multi-functional agents: Inhibition of acetylcholinesterase, butyrylcholinesterase, and Aβ aggregation and antioxidant activity.
TL;DR: Kinetic studies and molecular modelling simulations of the AChE-inhibitor complex indicated that a mixed-competitive binding mode existed for these berberine derivatives, and demonstrated that these hybrids displayed interesting activities, including Aβ aggregation inhibition and antioxidant properties.
41